An investigation into the release of cefuroxime axetil from taste-masked stearic acid microspheres - Part 1: The influence of the dissolution medium on the drug release profile and the physical integrity of the microspheres

International Journal of Pharmaceutics

Volumn 190, Issue 2, 1999, Pages 183-192

  Robson, H J ^a   Craig, D Q M ^a   Deutsch, D ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cefuroxime axetil; Stearic acid microspheres; Taste

Indexed keywords

CEFUROXIME; CEFUROXIME AXETIL; MICROSPHERE; STEARIC ACID;

ARTICLE; CHEMICAL COMPOSITION; CHEMICAL REACTION; DIFFUSION; DRUG RELEASE; DRUG SOLUBILITY; PH; PRIORITY JOURNAL;

CEFUROXIME; CEPHALOSPORINS; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PRODRUGS; SOLUBILITY; STEARIC ACIDS; TASTE;

EID: 0032751220     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00261-6     Document Type: Article

References (32)

1. Aronson J.K., Hardman M. Patient compliance. Br. Med. J. 305:1992;1009-1011.
2. Asaka, T., Misawa, Y., Kashimura, M., Morimoto, S., Watanabe, Y., Hatayama, K., 1994. 2′-Modified erythromycin or derivative thereof. EP application no. 0 553 353 A1 to Taisho Pharmaceutical Company Ltd.
3. Baddour L.M., Gibbs R.S., Mertz G., Cocchetto D.M., Noble R.C. Clinical comparison of single-oral-dose cefuroxime axetil and amoxicillin with probenecid for uncomplicated conococcal infections in women. Antimicrob. Agents Chemother. 33:1989;801-804.
4. Behrens R.H., Warburton B., Voller A., Odidi A., Pryce D. The bioavailability of a novel taste-masked formulation of quinine. Trop. Doct. 22:1992;10.
5. Beren A.R., Hopfenberg H.B. Diffusion relaxation in glassy polymer powders: 2. Separation of diffusion and relaxation parameters. Polymer. 19:1978;489.
6. Blase, C.M., Shaw, M.N, 1993. Aqueous pharmaceutical suspension for pharmaceutical actives. EP application no. 0 556 057 B1 to McNeil-PPC Inc.
7. Block, J., Cassiere, A., Christen, M.O, 1990. Neue arzneiform. DE 39 00 811 A1 to Kali-Chemie Pharma.
8. Cherukuri, S.R., Chau, T.L, 1991. Delivery system for cyclic amino acids with improved taste, texture and compressibility. EP application no. 0 458 751 A1 to Warner-Lambert Company.
9. Crisp, H.A., Clayton, J.C., Elliott, G., Wilson, M, 1989. Preparation of a highly pure, substantially amorphous form of cefuroxime axetil. USP no. 4,820,833 to Glaxo Group Ltd.
10. Dupuis L. Oral, liquid medications - relative palatability's. Can. J. Hosp. Pharm. 38:1985;9.
11. Eby, G.A. III, 1992. Flavour stable zinc acetate compositions for oral absorption. USP no. 5 095 035.
12. Foord R.D. Cefuroxime: human pharmacokinetics. Antimicrob. Agents Chemother. 9:1976;741-747.
13. Ginsburg C.M., McCracken G.H., Petruska M., Olson K. Pharmacokinetics and bactericidal activity of cefuroxime axetil. Antimicrob. Agents Chemother. 28:1985;504-507.
14. Gooch W.M., Swenson E., Higbee M.D., Cocchetto D.M., Evans E.C Cefuroxime axetil and penicillin V compared in the treatment of group A beta-hemolytic streptococcal pharyngitis. Clin. Ther. 9:1987;670-677.
15. Gregory, S.P., Jozsa, A.J., Kaldawi, R.E, 1990. Non-effervescent ibuprofen compositions. EP application no. 0 418 043 A1 to Nicholas Kiwi Pty. Ltd.
16. Harding S.M., Williams P.E.O., Ayrton J. Pharmacology of cefuroxime as the 1-acetoxyethyl ester in volunteers. Antimicrob. Agents Chemother. 25:1984;78-82.
17. Hussein, M.M., Barcelon, S.A, 1991. Flavor enhancing and medicinal taste masking agent. USP no. 4 983 394 to Warner Lambert Co.
18. Katsuragi Y., Kurihara K. Specific inhibitor for bitter taste. Nature. 365:1993;213-214.
19. Langer R.S., Peppas N.A. Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials. 2:1981;201-214.
20. Lu M.Y.F., Borodkin S., Woodward L., Li P., Diesner C., Hernandez L., Vadnere M. A polymer carrier system for taste masking of macrolide antibiotics. Pharm. Res. 8:1991;706-712.
21. Motola S., Agisim G.R., Mogavero A Palatable ibuprofen solutions. USP no. 5,024,997 to American Home Products Corporation Pharmaceutical Codex (1994). 1991;Pharmaceutical Press, London.
22. Powell D.A., Nahata M.C., Powell N.E., Ossi M.J. The safety, efficacy, and tolerability of cefuroxime axetil suspension in infants and children receiving previous intravenous antibiotic therapy. Ann. Pharmacother. 25:1991;1236-1238.
23. Roche, E.J., Reo, J.P, 1994. Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets. EP application no. 0 411 952 A2 to McNeil-PPC Inc.
24. Roy, G.M, 1994. Taste masking in oral pharmaceuticals. Pharm. Tech. Eur. 24-35.
25. Ryan D.M., O'Callaghan C.H., Muggleton P.W. Cefuroxime, a new cephalosporin antibiotic: activity in vivo. Antimicrob. Agents Chemother. 9:1976;520-525.
26. Shalit I., Dagan R., Engelhard D., Ephros M., Cunningham K. Cefuroxime efficacy in pneumonia: sequential short-course iv/oral suspension therapy. Isr. J. Med. Sci. 30:1994;684-689.
27. Shiozawa, H., Sugao, H., Yamazaki, S., Yano, K, 1993. Quick release coated preparation. EP application no. 0 559 897 A1 to Yamanouchi Pharmaceutical Co. Ltd.
28. St. Claire R.L., Caudill W.L. Stability of cefuroxime axetil in beverages. Am. J. Hosp. Pharm. 46:1989;256.
29. St. Claire R.L., Wilbourne D.K., Caudill W.L. Stability of cefuroxime axetil in apple juice. Paediatr. Infect. Dis. 7:1988;744.
30. Sutananta W., Craig D.Q.M., Newton J.M. An evaluation of the mechanisms of drug release from glyceride bases. J. Pharm. Pharmacol. 47:1995;182-187.
31. Sutananta W., Craig D.Q.M., Newton J.M. An investigation into the effects of preparation conditions and storage on the rate of drug release from pharmaceutical glyceride bases. J. Pharm. Pharmacol. 47:1995;355-359.
32. Wheatley, T.A., Erkoboni, D.F, 1992. Taste-masked medicaments and their preparation. PCT International Application, WO 92/19209 to FMC Corporation.